Skip to main content
Premium Trial:

Request an Annual Quote

Epitome to Develop Custom Assays for Bristol-Myers Squibb

NEW YORK, Jan. 4 (GenomeWeb News) - Epitome Biosystems said today that it has signed a technology access and product development agreement with Bristol-Myers Squibb to use its EpiTag protein-measurement platform.

 

Under the agreement, Epitome will design custom antibody arrays to measure proteins specified by Bristol-Myers Squibb to accelerate its clinical development programs. In return, Epitome will receive development funding and license fees from Bristol-Myers Squibb.

 

The EpiTag technology uses an in silico approach to identify peptide tags for any protein based on sequence information, Epitome said. The company said the platform enabled the development of multiplex protein assays.

Financial details were not discussed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.